Five Eleven Pharma Inc.

University of Pennsylvania

Karl Ploessl

Hank F Kung

Seok Rye Choi

Zhihao Zha

Zehui Wu

Futao Liu

Craig B Thompson

Wenchao Qu

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application

The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [Ga]GaClwith high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.

Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

The present invention is directed single diasteromers of 4-fluoroglutamine having a diastereomeric excess of at least 80%. Methods of preparing the single diastereomers are also described, as well as methods of using the single diastereomers of radiolabeled 4-fluoroglutamine as imaging agent is also described.

Single diastereomers of 4-fluoroglutamine and methods of their preparation and use

Growing community of inventors

Wilmington, DE, United States of America

Karl Ploessl